Bioactive Glasses as Carriers of Cancer-Targeted Drugs : Challenges and Opportunities in Bone Cancer Treatment
The treatment of bone cancer involves tumor resection followed by bone reconstruction of the defect caused by the tumor using biomaterials. Additionally, post-surgery protocols cover chemotherapy, radiotherapy, or drug administration, which are employed as adjuvant treatments to prevent tumor recurrence. In this work, we reviewed new strategies for bone cancer treatment based on bioactive glasses as carriers of cancer-targeted and other drugs that are intended for bone regeneration in conjunction with adjuvant treatments. Drugs used in combination with bioactive glasses can be classified into cancer-target, osteoclast-target, and new therapies (such as gene delivery and bioinorganic). Microparticulated, nanoparticulated, or mesoporous bioactive glasses have been used as drug-delivery systems. Additionally, surface modification through functionalization or the production of composites based on polymers and hydrogels has been employed to improve drug-release kinetics. Overall, although different drugs and drug delivery systems have been developed, there is still room for new studies involving kinase inhibitors or antibody-conjugated drugs, as these drugs have been poorly explored in combination with bioactive glasses.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
Materials (Basel, Switzerland) - 15(2022), 24 vom: 19. Dez. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Borges, Roger [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Bioactive glasses |
|---|
| Anmerkungen: |
Date Revised 26.12.2022 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3390/ma15249082 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM350684197 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM350684197 | ||
| 003 | DE-627 | ||
| 005 | 20231226045540.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/ma15249082 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1168.xml |
| 035 | |a (DE-627)NLM350684197 | ||
| 035 | |a (NLM)36556893 | ||
| 035 | |a (PII)9082 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Borges, Roger |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Bioactive Glasses as Carriers of Cancer-Targeted Drugs |b Challenges and Opportunities in Bone Cancer Treatment |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 26.12.2022 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a The treatment of bone cancer involves tumor resection followed by bone reconstruction of the defect caused by the tumor using biomaterials. Additionally, post-surgery protocols cover chemotherapy, radiotherapy, or drug administration, which are employed as adjuvant treatments to prevent tumor recurrence. In this work, we reviewed new strategies for bone cancer treatment based on bioactive glasses as carriers of cancer-targeted and other drugs that are intended for bone regeneration in conjunction with adjuvant treatments. Drugs used in combination with bioactive glasses can be classified into cancer-target, osteoclast-target, and new therapies (such as gene delivery and bioinorganic). Microparticulated, nanoparticulated, or mesoporous bioactive glasses have been used as drug-delivery systems. Additionally, surface modification through functionalization or the production of composites based on polymers and hydrogels has been employed to improve drug-release kinetics. Overall, although different drugs and drug delivery systems have been developed, there is still room for new studies involving kinase inhibitors or antibody-conjugated drugs, as these drugs have been poorly explored in combination with bioactive glasses | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a bioactive glasses | |
| 650 | 4 | |a bisphosphonates | |
| 650 | 4 | |a bone cancer | |
| 650 | 4 | |a drug delivery | |
| 650 | 4 | |a molecular-targeted therapy | |
| 700 | 1 | |a Pelosine, Agatha Maria |e verfasserin |4 aut | |
| 700 | 1 | |a de Souza, Ana Carolina Santos |e verfasserin |4 aut | |
| 700 | 1 | |a Machado, Joel |c Jr |e verfasserin |4 aut | |
| 700 | 1 | |a Justo, Giselle Zenker |e verfasserin |4 aut | |
| 700 | 1 | |a Gamarra, Lionel Fernel |e verfasserin |4 aut | |
| 700 | 1 | |a Marchi, Juliana |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Materials (Basel, Switzerland) |d 2009 |g 15(2022), 24 vom: 19. Dez. |w (DE-627)NLM208535349 |x 1996-1944 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2022 |g number:24 |g day:19 |g month:12 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/ma15249082 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2022 |e 24 |b 19 |c 12 | ||